Regular Article
Increase in prevalence of nosocomial non- Candida albicans candidaemia and the association of Candida krusei with fluconazole use

https://doi.org/10.1053/jhin.2001.1131Get rights and content

Abstract

Candida is an important nosocomial pathogen. This study was undertaken to provide information on the rate of candidaemia, to define the risks for candidaemia and to describe and account for the epidemiology of candidaemia at our institution between 1992 and 1999. The overall rate was 0.052 per 1000 patient days and 0.27 per 1000 discharges. The major risks for candidaemia were colonization at a non-sterile site (OR 3.85, 95%CI 1.80–9.09), total parenteral nutrition (TPN) in the absence of neutropenia (OR 11.8, 95%CI 4.5–35.4, P<0.001) and neutropenia in the absence of TPN (OR 3.7, 95%CI 1.8–7.7, P<0.001). There was no change in the overall incidence of candidaemia but there was a steady decline in the rate of C. albicans with a corresponding rise in the incidence of non- C. albicans species. C. krusei was highly associated with fluconazole exposure (χ2=20.78,P <0.001). There was no evidence of spread of C. krusei using random amplification of polymorphic DNA, suggesting the appearance of this organism was due to the selection pressure exerted by fluconazole.

References (38)

  • SK Fridkin et al.

    Epidemiology of nosocomial fungal infections

    Clin Microbiol Rev

    (1996)
  • JL Goodman et al.

    A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

    N Engl J Med

    (1992)
  • MA Slavin et al.

    Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study

    J Infect Dis

    (1995)
  • C Rotstein et al.

    Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian FluconazoleProphylaxis Study Group

    Clin Infect Dis

    (1999)
  • G Alangaden et al.

    Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. The Bone Marrow Transplantation Team

    Bone Marrow Transplant

    (1994)
  • DJ Winston et al.

    Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial

    Ann Intern Med

    (1993)
  • SB Wey et al.

    Risk factors for hospital-acquired candidemia. A matched case-control study

    Arch Intern Med

    (1989)
  • AD Dean et al.

    Epi Info, Version 6: a word processing, database, and statistics program for epidemiology on micro-computers

    (1990)
  • R Kennett et al.

    Modern Industrial Statistics

    (1998)
  • Cited by (111)

    • Changes in the utilization patterns of antifungal agents, medical cost and clinical outcomes of candidemia from the health-care benefit expansion to include newer antifungal agents

      2019, International Journal of Infectious Diseases
      Citation Excerpt :

      Particularly, non-albicans Candida species constitute larger proportions of candidemia isolates than in the past years (Diekema et al., 2012). Some of these species are relatively less susceptible or resistant to fluconazole (Hope et al., 2002; Playford and Sorrell, 2007). In general, echinocandins are fungicidal against most Candida species and resistance is rare (Colombo et al., 2010; Sucher et al., 2009).

    • Fluconazole non-susceptible breakthrough candidemia after prolonged low-dose prophylaxis: a prospective FUNGINOS study

      2018, Journal of Infection
      Citation Excerpt :

      A concomitant emergence of non-albicans Candida spp. with decreased susceptibility or intrinsic resistance to fluconazole, in particular Candida krusei and Candida glabrata, has been described. This shift has been reported in breakthrough candidemia (BTC) occurring on fluconazole.8–17 A microbiological study in Candida isolates from BTC described a correlation between dose of fluconazole and minimal inhibitory concentration (MIC), without reporting related clinical data.18

    • Treatment of infection in burn patients

      2018, Total Burn Care: Fifth Edition
    • Treatment of Infection in Burn Patients

      2017, Total Burn Care, Fifth Edition
    View all citing articles on Scopus
    f1

    Author for correspondence: Dr W. Hope, Department of Microbiology, Princess Alexandra Hospital, Ipswich Rd, Woolloongabba Q 4102, Australia. Fax : +61732405786; E-mail:[email protected]

    View full text